»
INDUSTRY NEWS
»
Distek, Inc. Releases the sensIR 3200 Disintegrator
Distek, Inc., an industry leader in pharmaceutical laboratory testing instruments, accessories and validation services, is pleased to announce the release of the sensIR 3200 – their next generation “Bathless” Disintegrator.
The Distek sensIR 3200 uses the latest in bathless heating to offer a disintegrator without the mess and drawbacks associated with conventional water bath-based instruments. By eliminating the water bath and utilizing a sleek modular design, Distek’s sensIR 3200 offers two, four or six disintegration test stations in the smallest foot print of any comparably equipped model.
The advanced features of the sensIR 3200 provide superior performance and functionality. With rapid media warm-up, the sensIR 3200 heats media from ambient to 37°C in less than 8 minutes, significantly increasing throughput by offering rapid changeover between testing.
The sensIR 3200’s color touch screen user interface was designed to provide the user with an intuitive and interactive tool to command the robust features. The icon driven interface lowers overall cost by reducing training time and user errors.
Each disintegration basket can operate independently or in unison, thus increasing throughput. The sensIR 3200 meets or exceeds all harmonized compendial design requirements.
Available Q1 – 2014, the sensIR 3200 will offer Auto Endpoint Detection using “Patent Pending” Near Infrared. This state-of-the- art technology provides endpoint detection without the need of a modified fluted disk, therefore eliminating the accelerated disintegration and disparity the use of a fluted disk can cause.
Jeff Seely, Vice President of Sales & Business Development says: “The release of the sensIR 3200 is another example of Distek’s innovation and leadership in the pharmaceutical testing market space. The use of IR to detect the presence of the tablet is a leap forward in disintegration testing providing reliable results and compliance with all monographs regardless if a fluted disk is required or not.”
New Microgram Weights with Nominal Values from 0.05 mg to 0.5 mg
METTLER TOLEDO is proud to announce the launch of a brand new range of microgram weights with nominal values from 0.05 mg to 0.5 mg. The microgram weights will allow National Measurement Institutes and customers with specialized nanotechnology applications to use the direct comparison method to verify weight values below 1 mg. The weights are available with a calibration certificate so customers can be assured of full traceability to the International Prototype Kilogram. METTLER TOLEDO is the only
80 | | November/December 2013
weights manufacturer in the world to offer calibrated weights with such low nominal values thanks to a joint venture with the British National Measurement Office.
At the extreme end of weights engineering, the nominal values of the weights range from 0.05 mg to 0.5 mg with an astounding level of uncertainty of just 0.0002 mg (0.2 micrograms). The microgram weights are available individually, as well as in a convenient kit containing specially designed accessories and handling tools. The kit provides users with everything they need for calibration of weights and mass verification in the microgram range.
The microgram weights range was developed largely in response to the needs of the nanotechnology market which typically involves the manufacture of objects with dimensions of less than 100 nanometers (smaller than one ten-millionth of a meter), for example: computer chips and microscopic devices. The microgram weights have a wide range of applications in the mechanical testing of nano- and bio-material sensors. For instance, they can be used to calibrate the very fine cantilever of an atomic force microscope which is drawn over an uneven object to reveal the surface contours at sub-nanometer level.
TAP Biosystems Group Plc Shareholders Approve Sartorius’ Takeover Offer
The shareholders of UK company TAP Biosystems Group plc approved Sartorius’ takeover offer at the shareholder meetings held yesterday. The cash offer made through Sartorius’ wholly-owned subsidiary Sartorius Stedim Biotech GmbH valued TAP Biosystems Group plc at approximately €33 million. The transaction is expected to close at the end of 2013.
The planned takeover of TAP Biosystems Group plc will enable Sartorius to further extend its bioprocess portfolio in the area of fermentation, especially in the early phases of product and process development. TAP Biosystems specializes in the design and development of smallscale, multi-parallel fermentation and cell culture systems for biopharmaceutical applications. Furthermore, TAP Biosystems’ portfolio includes automated cell processing systems and other benchtop equipment. Founded in 1987, the company is headquartered in Royston, UK. TAP Biosystems generated sales revenue of approximately €26 million in 2012/2013 and employs around 160 people worldwide.
Integrated Biological Research is Accelerating Drug Development for Neurodegenerative Diseases
Agilent Technologies Inc. announced that Dr. Junying Yuan, a pioneer and leading researcher in the fi eld of cell death at the Chinese
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92